Dr William Alazawi, MA(Cantab) MB BChir PhD MRCP
Reader & Consultant in Hepatology
Email: email@example.comTelephone: 020 7882 7195
He conducted his doctorate research in Professor Coleman’s laboratory at the MRC Cancer Cell Unit and discovered that a dominant host response to viral integration is altered interferon responsiveness. He moved to London to work with Professor Foster and studied the role of STAT2 as a pivotal signalling mediator in TLR-mediated inflammation. He became an NIHR Clinical Lecturer in 2011 and has been funded by the Academy of Medical Sciences. He held the prestigious Physician Scientist Fellowship of the European Association for the Liver 20134-2015 and currently holds a New Investigator Award from the Medical Research Council.
Clinical trials in non-alcoholic steatohepatitis
Professor Graham Foster (QMUL)
Professor Robert Goldin (Imperial College)
Professor Saheer Gharbia (Public Health England)
Dr Alastair O’Brien (UCL)
EMIF (European Medical Information Framework) network
Dr William Alazawi is a Reader and Consultant Hepatologist at Queen Mary, University of London and Bart’s Health NHS Trust. He qualified from the MB/PhD Programme in Cambridge and trained at Addenbrooke’s, Hammersmith, Royal London and King’s College Hospitals.
Death rates from liver disease are rising across the world, despite the fact that the leading causes of liver disease (non-alcoholic fatty liver disease (NAFLD), alcohol and chronic viral infections) are preventable or treatable. Our understanding of the development of chronic liver diseases (regardless of the cause) is that persistent injury occurs alongside exaggerated or inappropriate inflammatory and repair responses. This leads to scarring or fibrosis and cirrhosis, which, in turn, can lead to liver failure and liver cancer.
The Alazawi group’s principal focus is the key early step in this process – inflammation. Our integrated research programme has a firm foundation in basic molecular and disease model discovery science, funded by the Medical Research Council. Our on-going translational projects utilise our expertise in inflammatory signalling to answer key clinical questions. To directly impact clinical care, we are developing innovative approaches to delivering services in primary and secondary care.
Current Research Projects:
- The Role of STAT2 in Inflammation in the liver and pancreas
- Immune and inflammatory and microbiome profiling in patients with Non-Alcoholic Fatty Liver Disease
- Innate Immune and Inflammatory predictors of sepsis in patients undergoing surgery to the liver and pancreas.
- Population studies investigating risk factors for NAFLD and its complications
Systemic inflammatory response syndrome (SIRS) after major abdominal surgery is predicted by early upregulation of TLR4 and TLR5. Lahiri R, Derwa Y, Bashir Z, Giles E, Torrance H, Owen H, O’Dwyer M, O’Brien A, Stagg A, Bhattacharya S, Foster G, Alazawi W. Annals of Surgery 2015 Epub.
A Practical Approach to Non-Alcoholic Fatty Liver Disease in Patients with Diabetes. Tai FWD, Syn WK, Alazawi W. Diabetic Medicine 2015. 32: 1121-33.
Population based study of non-alcoholic fatty liver disease (NAFLD) shows disease is more common among Bangladeshis in ethnically diverse boroughs of London. Alazawi W, Abeysekera K, R. Mathur, J. Robson, Boomla K, Hull S, Foster GR. British Journal of General Practice, 2014. 64:694-702.
Elevated prostaglandin E2 mediates immune suppression in acute-on-chronic liver failure. O’Brien A, Fullerton J, Newson J, Massey K, Sewell, Hobbs A, Alazawi W, Winstanley A, Nicolaou A, Gilroy D. Nature Medicine, 2014. 20:518-23.
Stat2 loss leads to cytokine-independent, cell-mediated lethality in LPS-induced sepsis. Alazawi W, Heath HE, Waters JA, Woodfin A, O’Brien A, Scarzello AJ, Lopez-Otalora Y, Jacobs M, Petts G, Goldin RD, Nourshargh S, Gamero AM, Foster GR. Proceedings of the National Academy of Science, USA, 2013 110(21) 8656-8661.
View all William Alazawi's Research Publications at: http://www.researchpublications.qmul.ac.uk